More on RNAZ

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/17/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

TransCode Therapeutics (NQ:RNAZ)
Delayed: 9.60 +0.27 (2.89%)
Prev. Close $9.33  
Open$10.03 
52 Wk High$ 
52 Wk Low$ 
Day High$10.03 
Day Low$9.11 
P/E N/A  
EPS$ 
Volume11,532 


Mar 3, 2026 04:09 PM Form DEFA14A Transcode Therapeutics,
Mar 3, 2026 04:08 PM Form 8-K Transcode Therapeutics, For: Mar 02
Mar 3, 2026 08:03 AM TransCode licenses cancer immunotherapy platform in stock deal
Mar 3, 2026 08:02 AM TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the
Feb 23, 2026 08:11 AM Form 8-K Transcode Therapeutics, For: Feb 23
Feb 23, 2026 08:01 AM TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
Feb 5, 2026 08:11 AM Form 8-K Transcode Therapeutics, For: Feb 05
Feb 5, 2026 08:04 AM TransCode submits IND amendment for phase 2a colorectal cancer trial
Feb 5, 2026 08:04 AM TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
Jan 7, 2026 12:39 PM Form SCHEDULE 13G/A Transcode Therapeutics, Filed by: SABBY MANAGEMENT, LLC
View All Articles

Entities mentioned with RNAZ

View All Entities